NCGC00032630-01 | 130016-75-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: NCGC00032630-01
• 英文别名: 2-(2,5-Dimethylpyrrol-1-yl)-3-phenyl-propanoic acid；2-(2,5-Dimethyl-pyrrol-1-yl)-3-phenyl-propionic acid；2-(2,5-dimethylpyrrol-1-yl)-3-phenylpropanoic acid
• CAS: 130016-75-0
• 化学式: C₁₅H₁₇NO₂
• mdl: MFCD02302095
• 分子量: 243.305
• InChiKey: CIUPYBFUPLMRLH-UHFFFAOYSA-N

物化性质

• 沸点：
  409.8±45.0 °C(Predicted)
• 密度：
  1.10±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.266
• 拓扑面积：
  42.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  NCGC00032630-01 、 四氢吡咯 以78%的产率得到
  参考文献：
  名称：

  KASHIMA, CHOJI;MARUYAMA, TATSUYA;FUJIOKA, YOKO;HARADA, KAZUO, J. CHEM. SOC. PERKIN TRANS. PT. 1,(1989) N, C. 1041-1046

  摘要：

  DOI：

文献信息

• Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same
  申请人：Mustelin Tomas

  公开号：US20090105240A1

  公开（公告）日：2009-04-23

  The present disclosure relates to methods for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure further relates to compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure also relates to methods for identifying compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome.

  本公开涉及治疗白血病、白血病前期病症、以及骨髓增生异常综合征和急性髓系白血病的方法。本公开还涉及可用于治疗白血病、白血病前期病症、以及骨髓增生异常综合征和急性髓系白血病的化合物。本公开还涉及用于识别可用于治疗白血病、白血病前期病症、以及骨髓增生异常综合征的化合物的方法。
• METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS
  申请人：Reed John C.

  公开号：US20090118135A1

  公开（公告）日：2009-05-07

  An assay for determining compounds that inhibit activity of a BCl-2 protein, or affect conversion of Bcl-2 from an antiapoptotic to a proapoptotic form are described. In addition, compounds that modulate the function of anti-apoptotic proteins such as Bcl-2 and related Bcl-2 family members are identified.
• METHODS FOR TREATING LEUKEMIA AND MYELODYSPLASTIC SYNDROME, AND METHODS FOR IDENTIFYING AGENTS FOR TREATING SAME
  申请人：Mustelin Tomas

  公开号：US20120095032A1

  公开（公告）日：2012-04-19

  The present disclosure relates to methods for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure further relates to compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure also relates to methods for identifying compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome.